About Us

Leading the way
in immunotherapy

About
us

Leading the way
in immunotherapy

Who We Are

Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering synthetic peptides with unique, antitumoral properties.

CyPep-1, the company’s lead candidate, is being developed as a first-in-class tumor membrane targeting agent for the treatment of solid tumors.

Management

CEO

Lars Prestegarden

CBO/CFO

Federico Grego

Director

Raj Airey

Head of Clinical Development

Cesar Pico

Clinical Project Manager

Jeanette Kamman

Lead CRA

Sandra Jansen

CMC Coordinator

Danny van Hoorn

Advisors

Rolf Bjerkvig

Ole-Erik Iversen

Bo Jesper Hansen

Xavier Luria

Board

Chairman

Stein-Christian Mohn

Board Member

Liv H. Dyrnes

Board Member

Kjell Bernstrøm